The treatment of AR-positive prostate cancer cells with AU-15330 reduced DNA accessibility at oncogenic enhancer elements and disrupted enhancer–promoter loops and AR and FOXA1 occupancy, thereby suppressing oncogenic gene expression. This evidence concerns the gene AR and Familial prostate cancer.